Table 3.

Adverse events in the ICIs plus platinum-etoposide group and platinum-etoposide group.

	ICIs plus platinum-based chemotherapy (n = 109)		Platinum-based chemotherapy (n = 115)
	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4
Any event	97 (89.0%)	50 (45.9%)	102 (88.7%)	48 (41.7%)
Any event leading to death	3 (2.8%)		5 (4.3%)
Adverse events in each group
Neutropenia	56 (51.4%)	30 (27.5%)	67 (58.3%)	35 (30.4%)
Nausea	76 (69.7%)	32 (29.4%)	76 (66.1%)	27 (23.5%)
Vomiting	64 (58.7%)	37 (33.9%)	69 (60.0%)	44 (38.3%)
Anemia	58 (53.2%)	22 (20.2%)	60 (52.2%)	31 (27.0%)
Decreased appetite	37 (33.9%)	10 (9.2%)	40 (34.8%)	22 (19.1%)
Asthenia	23 (21.1%)	8 (7.3%)	17 (14.8%)	8 (7.0%)
Pneumonia	10 (9.2%)	2 (1.8%)	8 (7.0%)	1 (0.9%)
Decreased platelet count	17 (15.6%)	4 (3.7%)	10 (8.7%)	2 (1.7%)
Constipation	23 (21.1%)	8 (7.3%)	25 (21.7%)	9 (7.8%)
Diarrhea	19 (17.4%)	7 (6.4%)	16 (13.9%)	6 (5.2%)
Hypertension	8 (7.3%)	1 (0.9%)	10 (8.7%)	1 (0.9%)
High cholesterol	12 (11.0%)	4 (3.7%)	4 (3.5%)	0